Open AccessCaspofungin dosage adjustments are not required for patients with Child–Pugh B or C cirrhosis
Author(s) -
Thierry Gustot,
Rob ter Heine,
Elisa Brauns,
Frédéric Cotton,
Frédérique Jacobs,
Roger J. M. Brüggemann
Publication year - 2018
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dky189
Subject(s) - cirrhosis , caspofungin , medicine , pharmacokinetics , gastroenterology , pharmacology , antifungal , amphotericin b , dermatology
Controversies remain over caspofungin dosage adjustments in cirrhosis, particularly Child-Pugh (CP) B or C. The product information for of caspofungin recommends a maintenance dose reduction from 50 to 35 mg for patients with CP-B cirrhosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom